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Despite recognition of the looming antibiotic crisis by
healthcare professionals, the number of new antibi-
otics reaching the clinic continues to decline sharply.
This study aimed to establish an antibiotic profiling
strategy using a panel of clinically relevant bacterial
strains to create unique biological fingerprints for
all major classes of antibiotics. Antibiotic mode of
action profile (BioMAP) screening has been shown
to effectively cluster antibiotics by structural class
based on these fingerprints. Using this approach,
we have accurately predicted the presence of known
antibiotics in natural product extracts and have dis-
covered a naphthoquinone-based antibiotic from
our marine natural product library that possesses
a unique carbon skeleton. We have demonstrated
that bioactivity fingerprinting is a successful strategy
for profiling antibiotic lead compounds and that Bio-
MAP can be applied to the discovery of new natural
product antibiotics leads.
INTRODUCTION
The development of antibiotic resistance in clinical settings
continues to impact therapeutic delivery options and health
outcomes both within the United States and around the world.
Resistance is acquired genetically (horizontal gene transfer or
gene mutation) and manifested either biochemically (enzymatic
inactivation and modification) or through target modification,
acquisition of multidrug efflux pumps, or overexpression of
target genes (Giedraitien _e et al., 2011). The emergence of resis-
tant pathogens in hospitals and the wider community is
becoming a growing concern, and global mortality rates from
drug-resistant bacterial infections continue to increase annually
(Boucher et al., 2009). Every year, almost 100,000 Americans die
from antibiotic-resistant infections acquired from hospitals,
largely because of the reduced effectiveness of existing drugs,
due to the development and propagation of drug resistance
mechanisms. It is estimated that the annual cost of this disease
burden on the US healthcare system is more than $21 billion, as
reported by the Infectious Diseases Society of America (Spell-Chemistry & Biology 19, 1483–149berg, 2010). Currently, more people in the United States die of
hospital-acquired methicillin-resistant Staphylococcus aureus
(MRSA) infections than of AIDS and tuberculosis combined
(Boucher et al., 2009).
Despite the need to combat antibiotic resistance, the
discovery of new antibacterial drugs has waned in recent years.
Between the introduction of quinolone-based drugs, such as
nalidixic acid in the early 1960s, and the introduction of oxazoli-
dinones in the year 2000, there was a dramatic innovation gap,
where no new antibiotic classes were brought to market (Walsh,
2003). This problem is actually understated using this metric,
because of the extended timeline required for obtaining US
Food and Drug Administration (FDA) approval for clinical use.
New antibiotics therefore originate from discoveries made
many years earlier, suggesting that, within the antibiotic pipeline,
there is a discovery void of unknown extent rather than a devel-
opment gap (Silver, 2011).
Most currently available antibiotics are derived from microbial
natural products, often through the semisynthetic derivatization
of fermentation products (Clardy et al., 2006). Over the last
15 years, antibiotic development has been largely restricted to
synthetic tailoring of a few core scaffolds to create second-
and third-generation analogs of first-generation drugs (Fisch-
bach and Walsh, 2009). Despite significant efforts to employ
target-based screening strategies to develop new drugs that
disrupt pathogen-specific cellular processes, this approach
has yielded little in the way of new therapeutic development
(Chan et al., 2004; Payne et al., 2007).
Given the fierce selection pressure exerted on bacterial
species in the open environment (e.g., soils or marine sedi-
ments), it is perhaps unsurprising that microbial sources have
proven to be such a successful source for the discovery of
antibiotics. Unfortunately, traditional natural product antibiotic
drug discovery programs are becoming increasingly inefficient
at finding new lead compounds. This is in large part due to the
repeated rediscovery of known compounds, which have little
commercial or clinical value. Numerous analytical dereplication
approaches exist, each of which has its own advantage in
terms of scale, sensitivity, and resolution. The most common
approach employs metabolomics-driven database systems to
find new compounds, either using UV absorbance profiles
and high-performance liquid chromatography (HPLC) retention
times (Lang et al., 2008) or by expanding these systems to
include mass spectral data using liquid chromatography-mass5, November 21, 2012 ª2012 Elsevier Ltd All rights reserved 1483
Table 1. List of Training Set Antibiotics
Antibiotic Class Antibiotic Name Primary Target
Cell Wall Synthesis Inhibitors
b-lactams (A) Penicillins [piperacillin (A1), carbenicillin (A2), ampicillin
(A3), penicillin G (A4), cloxacillin (A5)], cephalosporins
[cefadroxil (A6), cefaclor (A7), ceftazidime (A8)]
Penicillin-binding proteins
Glycopeptides Vancomycin (M1) Peptidoglycan units terminal D-Ala-D-Ala dipeptide
Lipopeptides Polymixin B (M2) Lipopolysaccharide in the outer membrane
Others Alafosfalin (M3) Peptidoglycan units terminal D-Ala-D-Ala dipeptide
Bacitracin (M4) C55-isoprenyl pyrophosphate
D-cycloserine (M5) D-alanine ligase and alanine racemase
Fosfomycin (M6) Uridine diphosphate (UDP)-N-acetylglucosamine-
3-enolpyruvyltransferase
DNA Synthesis Inhibitors
Fluoroquinolones (B) Nalidixic acid (B1), ciprofloxacin (B2), levofloxacin (B3),
sparfloxacin (B4), norfloxacin (B5)
Topoisomerase II (DNA gyrase), topoisomerase IV
Sulfonamides (C) Sulfamethazine (C1), sulfapyridine (C2), sulfamethoxazole
(C3), sulfadiazine (C4), sulfamerazine (C5)
Competitive inhibitor for DHPS involved in folate
synthesis
Others Novobiocin (M18) DNA gyrase
RNA Synthesis Inhibitors
Rifamycins (D) Rifampicin (D1), rifabutin (D2), rifaximin (D3) DNA-dependent RNA polymerase
Resistomycins (E) Resistomycin (E1), resistoflavin (E2) RNA polymerase
Protein Synthesis Inhibitors
Tetracyclines (F) Oxytetracycline (F1), doxycycline (F2), tetracycline (F3),
demeclocycline (F4), minocycline (F5)
30S ribosome (inhibit aminoacyl tRNA binding to
ribosome)
Aminoglycosides (G) Tobramycin (G1), gentamicin (G2), amikacin (G3),
streptomycin (G4), spectinomycin (G5)
30S ribosome (mistranslation by tRNA mismatching)
Macrolides (H) Erythromycin (H1), clarithromycin (H2), midecamycin (H3),
roxithromycin (H4), spiramycin (H5), azithromycin (H6)
50S ribosome (stimulating dissociation of the peptidyl-
tRNA molecule from the ribosomes during elongation)
Amphenicols (I) Chloramphenicol (I1), thiamphenicol (I2), florfenicol (I3) 50S ribosome (inhibit elongation step)
Lincosamides (J) Clindamycin (J1), lincomycin (J2) 50S ribosome (stimulate dissociation of the peptidyl-
tRNA molecule from the ribosomes during elongation)
Pleuromutilins Tiamulin (M7) 50S ribosome (prevent correct positioning of the cytosine-
cytosine-adenine ends of tRNA for peptide transferase)
Others Thiostrepton (M8) 50S ribosome (inhibits messenger RNA-tRNA
translocation by the GTPase elongation factor G)
DNA Replication (Intercalators)
Anthracyclines (K) Doxorubicin (K1), epirubicin (K2), idarubicin (K3) Intercalate DNA/RNA strand and topoisomerase II
Others Actinomycin D (M9) Intercalates G-C base pairs and minor groove DNA
at the transcription initiation complex
Mithramycin (M10) Intercalates GC-rich DNA strand
Tetracenomycin (M11) Intercalates DNA
Anaerobic DNA Inhibitors
Nitrofurans (L) Furazolidone (L1), nitrofurantoin (L2) Highly reactive reduced form (by nitrofuran reductase)
Nitro-imidazole Ornidazole (M12) Damages bacterial DNA
Others
Antimycin A (M13) Qi site of cytochrome C reductase
Bafilomycin (M14) Vacuolar-type H+-ATPase (inhibits proton transport
across membrane)
Monensin (M15) Membrane ionophore
Netropsin (M16) DNA replication (binds minor groove of AT-rich double
stranded DNA)
Nonactin (M17) Membrane ionophore
Salinomycin (M19) Membrane ionophore
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Table 1. Continued
Antibiotic Class Antibiotic Name Primary Target
Staurosporine (M20) Protein kinase C (prevents ATP binding to the kinase)
Streptonigrin (M21) DNA and RNA synthesis (DNA and topoisomerase II)
Tunicamycin (M22) Glycoprotein synthesis (UDP-GlcNAc and Dol-P)
Valinomycin (M23) Membrane ionophore
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BioMAP Screening for Natural Products Discoveryspectrometry (LCMS) (Genilloud et al., 2011). Increasingly, use of
capillary nuclearmagnetic resonance (NMR) probes is also being
included to obtain NMR spectra of lead compounds at an early
stage in the discovery process. (Hu et al., 2005; Lambert et al.,
2007; Lin et al., 2008; Mitova et al., 2008; Wolfender et al.,
2011). However, these high-resolution approaches are low
throughput (HPLC analysis has to be done individually for each
sample) and often require access to sophisticated machinery
(intensive use high mass accuracy LCMS or capillary NMR). In
addition, these systems are driven by pattern matching based
on physicochemical properties and do not compare compounds
based on biological properties. It is therefore often difficult to
recognize new compounds that belong to well-established
compound classes if these new compounds possess different
physical characteristics (molecular weight, retention time, and
NMR resonances) than the library of known compounds used
for compound identification.
To take advantage of the vast molecular diversity offered by
natural product libraries, additional methods are needed to
selectively highlight compounds with unique biological proper-
ties rather than chemical fingerprints. This study aimed to over-
come the shortcomings in early dereplication by providing a
high-throughput and accessible platform that provides detailed
biological characterization of antibacterial properties for
screening libraries and that can be used to identify new lead
compounds with unique biological profiles. We have established
a panel of clinically relevant bacterial pathogens, including both
Gram-positive and Gram-negative strains that can reveal char-
acteristic ‘‘fingerprint’’ profiles for each antibiotic class. We
have termed this fingerprinting strategy the antibiotic mode of
action profile (BioMAP) screen.
Almost universally, derivatives of antibiotics from within the
same structural class function by the same mode of action. This
study examined the hypothesis that antibiotics from the same
structural class would possess similar biological activity profiles
across a panel of bacterial pathogens and that this profile could
be used to cluster unknown compounds by structural class.
This approach is analogous to the National Cancer Institute 60-
cell line screen, which employs differences in the activities of
test drugs against a large panel of cancer cell lines to predict
molecular targets by comparison of these profiles with those for
compoundswithknown targets.Todevelop theBioMAPplatform,
we have profiled both commercially available FDA-approved
drugs and prefractionated extracts from type strains of micro-
organisms known to produce specific antibiotics and have shown
that these profiles are diagnostic for the presence of specific
compound classes and that we can predict the presence of these
compounds directly from natural product prefractions.
In addition to screening pure antibiotics and type strain pre-
fractions, we have expanded the screening program to includeChemistry & Biology 19, 1483–1493,120 prefractions from our marine-derived actinobacterial
library. These prefractions are prepared by fractionation of crude
extracts into six subfractions using solid-phase extraction C18
chromatography (Supplemental Experimental Procedures avail-
able online) as a standard component of our natural product
discovery program, in order to generate materials of reduced
complexity for biological screening. Clustering of the BioMAP
profiles from these prefractions indicated the presence of
several known antibiotics, including actinomycin D, whose pres-
ence in the prefraction was confirmed through a combination of
LCMS andNMR studies. In addition, BioMAP clustering revealed
a number of extracts with unique profiles that did not match
those of the training set. Examination of one of these extracts
led to the isolation of a structurally unique naphthoquinone anti-
biotic, which we have named arromycin. This metabolite has an
unprecedented carbon skeleton and is part of only a small family
of naturally occurring naphthoquinones possessing this substi-
tution pattern.
RESULTS
BioMAP Analysis of Commercially Available Antibiotics
The BioMAP screening platform was created by selecting a total
of 15 bacterial strains, including organisms of relevance in
both clinical and laboratory settings. The panel consisted of six
Gram-positive strains (BSL1: Bacillus subtilis, Staphylococcus
epidermis, Enterococcus faecium, Listeria ivanovii; BSL2:
S. aureus, MRSA) and nine Gram-negative strains (BSL1:
Escherichia coli, Acinetobacter baumanii, Enterobacter aero-
genes, Ochrobactrum anthropi, Providencia alcalifaciens;
BSL2: Yersinia pseudotuberculosis, Pseudomonas aeruginosa,
Salmonella typhimurium, and Vibrio cholerae).
Initially, a training set of 72 commercially available antibiotics
was selected for profiling to examine the accuracy of the
BioMAP platform for clustering compounds by antibiotic class.
This training set (Table 1) was designed to cover both the major
mechanisms of action of current antibiotics and the more
commonly encountered classes of microbially derived natural
products. These included cell wall biosynthesis inhibitors
(b-lactams, glycopeptides, and lipopeptides), protein synthesis
inhibitors (tetracyclines, macrolides, aminoglycosides, amphe-
nicols, lincosamides, and pleuromutilins), RNA synthesis inhibi-
tors (rifamycins and resistomycins), nucleic acid biosynthesis
inhibitors (fluoroquinolones and sulfonamides), DNA-damaging
agents (nitrofurans and nitroimidazoles), as well as a number of
additional targets.
Parallel screening of dilution series (2-fold dilutions, 100 mM–
0.2 nM) of training set compounds against all 15 strains in 384
well liquid culture growth inhibition assays provided simulta-
neous determination of minimum inhibitory concentrations5, November 21, 2012 ª2012 Elsevier Ltd All rights reserved 1485
Figure 1. Schematic of BioMAP Screening
Platform
Serially diluted prefractions were screened against
a panel of 15 pathogenic bacterial strains in 15
different 384 well assay plates. MICs were deter-
mined by observing the growth curves generated
from OD600 values recorded hourly over a 24 hr
period. Activity fingerprinting profiles for each
prefraction were plotted using normalized MIC
values and compared to 72 established profiles of
known drugs from 12 major classes of antibiotics.
Early dereplication of known bioactive compounds
in prefractions permits the efficient selection of
extracts with unique biological profiles for further
analysis.
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isms. Internal normalization of these MIC values across the
screening panel was then applied to create a concentration-
independent BioMAP profile for each member of the training
set, with values ranging from 0 (inactive) to 1 (most potent)
(Figure 1).
Clustering of BioMAP profiles for the training set using hierar-
chical clustering methods revealed a strong structure—BioMAP
dependence for 10 of the 12 compound classes (Figure 2).
Of these, six of the ten classes (fluoroquinolones, rifamycins,
resistomycins, amphenicols, aminoglycosides, and nitrofurans)
showed perfect clustering, with all representatives of the class
clustered together in a contiguous array. In three further exam-
ples (macrolides, anthracyclines, and tetracyclines), the clusters
contained just one outlier, with the remainingmembers clustered
together in a single array. In one example (b-lactams), the large
cluster contained five members, with a further three members
as outliers to the main cluster. Finally, one class (lincosamides)
showed weak MIC values and corresponding weak clustering,
while the sulfa drugs possessed in vitro activities too weak to
provide measurable BioMAP profiles up to the highest concen-
trations tested.
As expected, compounds that were unique within the
training set in terms of both structure and molecular target
(e.g., polymixin B) did not cluster with any other training set
members. In addition, there was little correlation between
compounds that target similar essential processes (e.g.,
protein synthesis) if these compounds did not also affect the
same targets (e.g., the tetracyclines and aminoglycosides,
which target different positions on the 30S ribosomal subunit;
Kohanski et al., 2010). Therefore, profiling of the 72-member
training set provided a validation of the BioMAP approach for
characterizing classes of antibiotic agents in terms of structural
and mechanistic similarities and provided encouragement to1486 Chemistry & Biology 19, 1483–1495, November 21, 2012 ª2012 Elsevier Ltd All rights reextend this platform to the evaluation
of natural product extracts.
Identification of Known Antibiotics
from Type Strains
In order to evaluate the accuracy of
BioMAP screening for predicting the
presence of specific natural products in
complex mixtures, we examined threetype strains known to produce compounds contained in the
training set. Liquid cultures of Saccharopolyspora erythraea
(American Type Culture Collection [ATCC] 11635; erythromycin
producer), Amycolatopsis mediterranei (ATCC 13685; rifamycin
SV producer), and Streptomyces aureofaciens (ATCC 10762;
tetracycline producer) were grown in shake flasks and extracted
and prefractionated using our standard protocol. Dilution series
of these prefractions were subjected to BioMAP profiling and the
resulting profiles compared to those from the training set. In all
cases, BioMAP profiles for the active prefractions closely
matched those of the relevant pure compounds (Figure 3) with
Pearson correlations of 0.9940 (erythromycin), 0.9094 (rifamy-
cin), and 0.8339 (tetracycline).
Presence of the predicted compounds in relevant prefractions
was confirmed by LCMS analysis and coinjections with known
standards in all cases. For the S. erythraea prefraction, an ex-
tracted ion chromatogram (EIC) for the [M+H]+ adduct of erythro-
mycin revealed a strong signal that matched the retention time
and ionization profile for commercial erythromycin (Figure 3A).
Similarly, strong EIC signals for the tetracycline [M + H]+ ion were
also observed in both the S. aureofaciens prefraction, and an
LCMSrunofacommercial sampleof tetracycline (datanot shown).
EIC analysis of the A. mediterranei prefraction revealed the pres-
ence of the known A. mediterranei metabolite rifamycin SV. This
compoundwas not amember of the original training set, however,
comparison of BioMAP profiles between three related training set
compounds (rifaximin, rifabutin, and rifampicin), and the rifamycin
SV-containing extract (Figure 3B) shows a strong correlation
between these four samples. These results indicate that BioMAP
screening can identify active constituents directly from extracts,
even in instances where the titer of the active constituent is
unknown. Further, these results show that it is possible to identify
compounds from specific compound classes, even if that exact
compound is not part of the initial training set.served
Figure 2. Cluster Heat Map of Training Set
Compounds
The cluster plot was generated using Cluster 3.0
software and displayed using TreeView v1.1.6.
Normalized MIC values (0 to 1) are represented
by a red-black color scheme with a gradient
from inactive (black) to most potent (red). The
panel of 15 bacterial strains, list of antibiotics
used in the training set, and clustering parame-
ters are described in the Experimental Proce-
dures. Antibiotics are color-coded and alphanu-
merically labeled (A–L) according to structural
class. ‘‘M’’ is assigned to antibiotics that are
single derivatives without other family members.
Compound activity profiles were clustered into
ten major subclusters, as annotated in the figure
above.
See also Tables S1A and S1B.
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Dereplication of KnownMetabolites by BioMAPProfiling
A library of 3,120 prefractionated natural product extracts was
subjected to BioMAP profiling using a two-stage screening
approach. Initially, all 3,120 prefractions were screened against
the panel of 15 pathogenic strains at a single concentration.
Eighty-three prefractions that showed activity against at least
four test strains were serially diluted (2-fold dilutions) and re-
screened against the entire test panel to generate BioMAP
profiles. Clustering of these BioMAP profiles with those of the
training set revealed both prefractions that clustered closely
with known compounds and those whose BioMAP profilesChemistry & Biology 19, 1483–1495, November 21, 2012 ªbore little correlation to the training
set. Organization of these profiles as
a cladogram (Figure 4) reveals branches
corresponding to each of the major
classes of antibiotics and illustrates the
integration of the natural product profiles
within the network. To test the accuracy
of this integration, we examined two
branches containing both natural pro-
duct prefractions and commercial antibi-
otics. Prefraction 1349D, which clustered
closely with the known bacterial natural
product actinomycin D, was evaluated
by peak library screening using a combi-
nation of LCMS-based fractionation and
biological screening. Comparison of
these results, coupled with compound
purification and NMR analysis (Fig-
ure S1A), revealed actinomycin D as the
active constituent of the extract, as pre-
dicted by BioMAP profiling (Figure 5). In
addition, examination of prefractions
1565C and 1565D, using a similar
approach, identified novobiocin as the
sole antibiotic component of these pre-
fractions (Figure S1B), in line with the
prediction from the BioMAP cladogram,
indicating that BioMAP screening cancorrectly predict the presence of specific antibiotics from pre-
fractions of environmental isolates.
Peak Library Screening of Extracts with Unique
BioMAP Profiles
To test the ability of BioMAP screening to identify prefractions
containing novel antibiotics, we selected several extracts from
the hierarchical cluster for further study. Of these, 1431E was of
particular interest, because it was part of a branch containing no
reference compounds. Peak library screening of this prefraction
against three Gram-positive strains (B. subtilis, S. aureus, and
MRSA) revealed one active constituent with a UV absorption2012 Elsevier Ltd All rights reserved 1487
Figure 3. BioMAP Profiles, Selected Cluster Plots, and HPLC Traces for Antibiotic-type Strains
(A) Pure erythromycin versus S. erythraea prefraction E.
(B) Pure rifampicin versus A. mediterranei prefraction C. Type strains that were known to produce specific antibiotics were used as controls to validate that
BioMAP screen can accurately annotate natural product extracts that contain multiple constituents. BioMAP profiles plotted using normalizedMIC values of type
strain prefractions (blue) were compared to those of pure antibiotics (red) and showed high similarities to one another. Comprehensive clustering of activity
profiles of the training set with these controls (heat map plots) further support these similarities. Ion extraction chromatograms from LCMS traces validate the
presence of erythromycin in the S. erythraea prefraction and rifamycin SV in the A. mediterranei prefraction.
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Figure 4. Cladogram Depicting the Global Clustering of Training Set Compounds, Type Strains, and Natural Product Prefractions
Hierarchical clustering showed the relationship between 62 commercially available antibiotics and 83marine natural product prefractions, including three control
type strains. Hierarchical clustering of BioMAP profiles for all prefractions and training set compounds was performed using MeV 4.8.1 (clustering parameters as
described in Experimental Procedures) and the output visualized in Cytoscape 2.8.2 as a cladogram. Training set compounds were color-coded by structural
class. Natural product prefractions are colored in red.
See also Tables S1A and S1B.
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microbial natural products in the Antimarin database (Blunt et al.,
2009). Subsequent large-scale culture of the producing organism
and purification of the active constituent by HPLC afforded 73mg
of a dark orange crystalline solid. Structure elucidation using
standard one- and two-dimensional NMR techniques (NMR
data: Figure S2) coupled with single-crystal X-ray diffraction anal-
ysisdetermined thestructureof thismetabolite as thenaphthoqui-
none natural product arromycin (1) (Figure 6). Briefly, electrospray
ionization time-of-flight high-resolution mass spectrometry anal-
ysis predicted the molecular formula C21H24O5. One- and two-Chemistry & Biology 19, 1483–149dimensional NMR experiments revealed the presence of seven
subunits (Figure S2), which accounted for all the atoms predicted
by the molecular formula. The presence of the 1,4-naphthoqui-
none moiety was supported by characteristic absorbances in
the UV spectrum at 216, 266, 320, and 410 nm (Charan et al.,
2005; Funayama et al., 1989; Ishibashi et al., 1991; Shin-ya
et al., 1990). However, in the presence of a strong four-bond het-
eronuclear multiple bond correlation (Figure S2B), one unob-
served resonance in the 13C spectrum, and C(4)/C(6) resonance
overlap (Figure S2Aii) within the naphthoquinone ring system
precluded the unambiguous assignment of the substitution5, November 21, 2012 ª2012 Elsevier Ltd All rights reserved 1489
Figure 5. Detection of the Known Compound Actinomycin D in a Natural Product Prefraction Using BioMAP Screening
(A) BioMAP profile comparison of pure actinomycin D (red) versus prefraction 1349D (blue) showed strong profile similarities.
(B) Activity plot of the peak library for prefraction 1349D and the corresponding HPLC trace. The peak library of 1349D was generated by collecting compound(s)
at one-minute intervals using an automated liquid chromatography fractionation system and subjecting this library to secondary screening against selected
bacterial strains (E. coli in light blue and A. baumanii in green). The bioactive compound that corresponded to the activity plot (boxed in red) was purified by HPLC.
Subsequent mass spectrometric and NMR analyses confirmed this metabolite as the known antibiotic actinomycin D.
See also Figure S1.
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cin from isopropanol followed by single-crystal X-ray diffraction
was employed to assign the structure, as depicted in Figure 6.
Biological Evaluation of Arromycin
Rescreening of arromycin as a pure compound confirmed its
antibacterial activity (B. subtilis, MIC = 25 mM; E. faecium,
MIC = 50 mM; L. ivanovii, MIC = 50 mM; MRSA, MIC = 25 mM;
S. aureus, MIC = 12.5 mM; S. epidermis, MIC = 12.5 mM) and
showed that the pure compound possessed a BioMAP profile1490 Chemistry & Biology 19, 1483–1495, November 21, 2012 ª2012that was consistent with the BioMAP profile of the original
prefraction (Figure 6C). Arromycin showed only mild cytotoxic
activity against HeLa cells, with an LD50 greater than the highest
tested concentration (60 mM).
DISCUSSION
Creation of BioMAP Profiles
To examine unknown natural product libraries using the BioMAP
system, we first created BioMAP profiles for a training set ofElsevier Ltd All rights reserved
Figure 6. Structure and Activity of Arromycin (1)
(A) Planar structure.
(B) Thermal ellipsoid plot of arromycin.
(C) Comparison of BioMAP profiles for prefraction 1431E and pure arromycin.
See also Figure S2 and Tables S2 and S3.
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(Table 1) by screening against 15 clinically relevant pathogenic
bacterial strains (Supplemental Experimental Procedures).
Almost all ‘‘ESCAPE’’ pathogens (E. faecium, S. aureus,
Clostridium difficile, A. baumanii, P. aeruginosa, and Enterobac-
teriaceae) (Peterson, 2009), a group of particularly problematic,
clinically associated bacteria, were included in the BioMAP
panel. Enterobacteriaceae is a large family of Gram-negative
bacteria that are well known for their pathogenicity; members
of this family in our panel include E. coli, E. aerogenes, Y. pseu-
dotuberculosis, andS. typhimurium. MICswere determined from
these data for each compound against each test strain, and
these values were converted to BioMAP profiles by an iterative
normalization and internal calibration strategy. The key to
success of this approach is the internal normalization of MICs
across the array of bacterial strains for every individual test
compound to create concentration-independent activity plots.
This allows comparison of patterns of activity instead of absolute
concentrations and can be applied to natural product extracts of
unknown constitution. BioMAP profiles are then ordered using
hierarchical clustering (Figure 2) to provide a measure of profile
similarities between compounds. To be successful, screening
dilution series must be sufficiently concentrated to identify
even weakly active hits against specific strains. Without this,
BioMAP profiles will not accurately classify test compounds,
because the absence of values for weak hits in the profile
reduces the similarity of these profiles to those from the training
set. In our experience, this is the primary reason for the occa-Chemistry & Biology 19, 1483–149sional failure of samples to cluster well with training set
compounds.
Examination of the hierarchical clustering diagram for the
training set of 72 known antibiotics (Figure 2) reveals excellent
profile matches for ten of the 12 classes of compounds tested
in the study (Table 1, compound groups A–L). Among the DNA
synthesis inhibitors, the five members of fluoroquinolones
(group B) that inhibit DNA replication by targeting bacterial
DNA gyrase and topoisomerase IV (Drlica and Zhao, 1997)
were clustered adjacently to one another, with the two most
structurally similar second generation members (ciprofloxacin
[B2] and norfloxacin [B5]) most tightly clustered together (corre-
lation = 0.9561). The two groups of RNA synthesis inhibitors
showed very reliable clustering, with the rifamycins (group D)
clustered with a correlation score of 0.8915 and the resistomy-
cins (group E) clustered with a correlation score of 0.9964. To-
bramycin (G1) and amikacin (G3) are the two most structurally
similar aminoglycosides, resembling kanamycin with three con-
tiguous amino sugars in the glycosidic portion; these two class
members showed good clustering, with a correlation score of
0.9352. Gentamicin (G2), streptomycin (G4), and spectinomycin
(G5) joined these members to form a single aminoglycoside
clade. For the macrolides (group H), except for azithromycin
(H6), which was separated from the main cluster by two outliers
(cloxacillin and lincomycin), all five members were clustered
closely together. Interestingly, these macrolides were clustered
in such a pattern that the three members (erythromycin [H1],
clarithromycin [H2], and roxithromycin [H4]) with a 14-membered5, November 21, 2012 ª2012 Elsevier Ltd All rights reserved 1491
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lation = 0.9808), while midecamycin (H3) and spiramycin (H5),
the 16-membered lactone ring derivatives, were more distantly
related.
In two cases (penicillins [A] and tetracyclines [F]), one of the
analogs was separated by a significant distance from the main
compound class cluster. In both instances, this separation can
be attributed to a narrower or broader spectrum of activity for
the outlier compared with the other members of the class. In
the case of cloxacillin (A5), the activity profile is one of the nar-
rower spectrum for this compound class, and it is employed
almost exclusively against b-lactamase-producing strains,
particularly Gram-positive cocci (Barber and Waterworth,
1964). By contrast, piperacillin (A1) is among the most versatile
of the penicillin derivatives, with an unusually broad spectrum
of antibacterial activity against Gram-negative bacilli compared
to ampicillin and carbenicillin (Verbist, 1978). Minocycline is
reported to possess a broader spectrum of activity compared
with othermembers of the tetracycline family due to its increased
lipophilicity. This improves its ability to penetrate both mamma-
lian tissues and bacterial cell walls (Bishburg and Bishburg,
2009) and explains its separation from the rest of the tetracycline
cluster. Overall, 36 of the 42 compounds in the training set
that were represented by multiple family members clustered
together, with the remaining six compounds either being outliers
to larger families or compounds belonging to smaller families
that showed weak clustering.
Although clustering was successful for compounds within
specific chemical classes, we did not observe close clustering
of compounds from different chemical classes with similar
biological targets. For example, lincosamides, amphenicols,
and macrolides all disrupt the entry or exit of transfer RNA
(tRNA) in the peptidyl transferase center (PTC) of the ribosomal
50S subunit. Although these compounds have all been shown
to overlap in the PTC binding site (Dunkle et al., 2010), the Bio-
MAP profiles for these three classes of compounds are markedly
different to one another (e.g., clindamycin versus chloramphen-
icol versus erythromycin). This is likely due to differences in
compound uptake and efflux between bacterial strains, which
result in BioMAP profiles that are influenced by both pharmaco-
kinetic properties and molecular targets. This result suggests
that, while the BioMAP platform is well suited to the classification
of compounds based on structural features, it is less well suited
to the direct prediction of biological targets from primary
screening data.
Identification of Known Natural Products
from Type Strains
The results from screening organic extracts of antibiotic type
strains indicate that BioMAP profiling cannot only predict the
presence of compounds contained in the training set (as is the
case with the erythromycin and tetracycline examples), but can
also predict the presence of structurally related compounds
that are not present as exact matches in the training set (rifamy-
cin SV versus rifaximin and rifampicin). These results indicate
that the BioMAP approach is capable of accurately identifying
compound classes that are present in the training set, whether
or not the exact compound is amember of the training set family.
In addition, these results show that compound identification can1492 Chemistry & Biology 19, 1483–1495, November 21, 2012 ª2012be accomplished even in complex mixtures without disruption
by other inactive constituents. Together these results strengthen
the BioMAP approach for novel antibiotic discovery through the
preselection of screening library members that possess profiles
not represented in the training set.
Discovery of Arromycin from a Natural Product Library
To probe the utility of this approach for the discovery of new
antibiotic scaffolds, we screened our prefractionated marine
natural product library for compounds with unique BioMAP
profiles. We selected one cluster (1390E, 1431E, and 1431F)
for further study because of its distant relationship to known
compound clusters and subjected one of these prefractions
(1431E) to peak library fractionation. Screening of this ‘‘one-
compound-one-well’’ peak library identified one component in
the mixture that was responsible for the observed BioMAP
profile. Purification of this compound by HPLC led to the isola-
tion of arromycin (1) as a dark orange crystalline solid.
Arromycin possesses a number of unusual structural features
for naphthoquinone antibiotics, including an unprecedented
1,2,4,4-tetrasubstituted cyclohexene ring connected to the 2
position of the naphthoquinone core via a methylene bridge. In
addition, the B ring of the naphthoquinone core is trisubstituted
as the 6,8-dihydroxy-7-methyl derivative, a motif with relatively
little precedent among marine microbially derived naphthoqui-
nones (Sunassee and Davies-Coleman, 2012).
Although naphthoquinones have previously been reported
as antimicrobial agents, this is the first report of a naphthoqui-
none scaffold containing a 2,4,4-trimethylcyclohexenyl C ring.
Isoprene-derived alkylation at the 2 position is a common feature
of naturally occurring quinones, hydroquinones, and naphtho-
quinones; however, the alkyl side chain in 1 is highly modified,
making it the first example of this scaffold.
The antibacterial spectrum of 1 was similar to previously re-
ported activities for other naphthoquinone antibiotics (Charan
et al., 2005; Matsumoto et al., 1999; Papageorgiou et al., 1999;
Riffel et al., 2002). Overall, 1 showed narrow-spectrum antibac-
terial activity against the Gram-positive strains in the bacterial
panel (B. subtilis, L. ivanovii, E. faecium, and the staphylococcal
strains). More broadly, naphthoquinones have been reported to
display bioactivities against a wide range of biological targets,
including micro-organisms, protozoan parasites, and mamma-
lian cells. In the area of antibiotics, the precise mode of action
of naphthoquinone drugs remains unclear. The FDA-approved
antimalarial drug atovaquone is sometimes used to treat
Pneumocystis carinii infections in patients with HIV and is
thought to function by the disruption of redox cycling through
interaction with cytochrome b (Kessl et al., 2004). In addition,
naphthoquinone scaffolds have been proposed to inhibit topo-
isomerase II and the production of reactive oxygen species
that contribute to DNA damage and cell death (Chung et al.,
2009), However, given the importance of substitution patterns
in defining antibacterial activities in naphthoquinone libraries
(Voskien _e et al., 2011), it is not clear whether either of these
targets are relevant to the observed antibacterial activity for
compound 1. Although the potency of 1 ismodest, this discovery
validates the hypothesis that BioMAP screening can be used to
identify structurally novel antibiotics as entry points for further
medicinal chemistry optimization.Elsevier Ltd All rights reserved
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Products
Cost efficiency and throughput are two of the most important
criteria in the design of good dereplication approaches. Over
the last 15 years, most major pharmaceutical companies have
left the natural products arena, because it has become increas-
ingly difficult to justify the substantial capital investment required
to discover novel lead compounds from natural sources. By
contrast, BioMAP profiling requires no investment in costly infra-
structure, such as LCMSorNMRcapacity. Instead, the approach
can be accomplished using only basic microbiology tools and
readily available liquid handling robotics. Using the 384 well
microtiter plate format, this high-throughput approach allows
screening to be done rapidly and in parallel, unlike HPLC, which
can only run one sample at a time (40 min/sample). The assay
has been designed to be small scale (30 ml screening volume),
which allows the use of very small quantities of test material.
TheBioMAP approach is fully scalable and customizable to alter-
native experimental designs. These could include the use of
different bacterial panels to identify new leads for specific path-
ogen targets or the inclusion of a greater number of analogs of
a specific compound class for programs aiming at expanding
the chemical space around a particular molecular scaffold.
One major challenge when dealing with natural product
screening is the determination of compound concentrations in
crude extracts. Because BioMAP profiles are internally normal-
ized, the resulting fingerprints are concentration-independent,
provided that compounds are screened at sufficiently high initial
concentrations. We have shown that natural product prefrac-
tions will cluster well with pure compounds from the training
set, provided that each natural product extract contains just
a single dominant antibiotic constituent.
One limitation of this technology is that thepresence ofmultiple
bioactive constituents in a single prefraction or crude extract will
result in ‘‘mixed-mode’’ BioMAP profiles that do not cluster well
with the training set, even if both compound classes are con-
tained in the set. For this reason, prefractionation of crude
extracts is preferable, as it simplifies the constitution of screening
materials and reduces the likelihood of obtaining mixed-mode
profiles. However, this technology is equally applicable to crude
extracts, provided that care is taken when prioritizing lead
extracts for follow up. One way to accomplish this is through
the use of peak library secondary screening. This has the dual
advantages of directly identifying all bioactive constituents for
a given extract and providing simultaneous BioMAP profiles for
each component. In this way, instances of mixed-mode profiles
can be quickly identified and the BioMAP profiles for contributing
components reclustered to place each individual constituent
within the cladogram. We have provided both the MICs and the
normalized BioMAP data for all training set antibiotics (Tables
S1A and S1B), making this tool readily accessible to the wider
drug discovery community, and hope that this will encourage
the use of this technology as one component of ongoing efforts
to develop new therapeutic options for bacterial infections.
SIGNIFICANCE
The BioMAP screening platform provides a target-indepen-
dent mechanism for classifying natural products by com-Chemistry & Biology 19, 1483–149pound class directly from complex mixtures. This screening
approach is both low-cost and high-throughput and is suit-
able for any research program that has access to a standard
plate reader. BioMAP screening offers new opportunities
for the discovery of natural product-based antibiotics
by circumventing the challenge of compound rediscovery
that has hampered recent efforts to develop novel anti-
biotic scaffolds from natural product sources. Because the
BioMAP strategy classifies compounds based on their
activity profiles rather than chemical characteristics, it is
capable of identifying both exact matches to compounds in
the trainingsetaswellasstructurally relatedcompoundsthat
are not represented within the training set. This approach is
therefore well positioned to identify structurally unique
antibiotics from screening libraries, as evidenced by
discovery of the naphthoquinone antibiotic arromycin.
EXPERIMENTAL PROCEDURES
FDA-Approved Antibiotics
Antibiotics for the training set were selected to cover all of themajor compound
classes currently available in the clinic, including 16 classes that function by
different modes of action (Table 1). Alphanumeric labels were given to each
drug to identify derivatives from the same antibiotic class. Screening plates
were generated by serially diluting antibiotics in DMSO (2-fold dilutions, final
screening concentrations 100 mM–0.2 nM). BioMAP profiles were plotted
according to normalized MIC values.
Preparation of Type-Strain Prefractions
Antibiotic-producing-type strains were purchased from ATCC (USA). Freeze-
dried pellets of S. erythraea (ATCC 11635; erythromycin producer),
A. mediterranei (ATCC 13685; rifamycin SV producer), and S. aureofaciens
(ATCC 10762; tetracycline producer) were revived with ISP Medium 1 (5 g
acid-hydrolyzed casein and 3 g yeast extract in 1 l distilled water) according
to the recommended protocol. Cultures were fermented, extracted, and
prefractionated in the same manner as the marine natural product libraries
(Supplemental Experimental Procedures) using ISP Medium 1 as the fermen-
tation medium. Serial dilution series were prepared for each prefraction, as
described above.
Biological Screening and Creation of BioMAP Profiles
Saturated overnight cultures of pathogenic strains were diluted 1:1000 and
dispensed into sterile clear polypropylene 384 well plates (30 ml screening
volume). DMSO solutions of test compounds (300 nl) were pinned into each
well at t0 using a high-throughput pinning robot (Perkin Elmer Janus MDT).
After compound addition, screening plates were stacked in an automated
plate reader/shaker (Perkin Elmer EnVision) and OD600 reading was collected
every hour for 24 hr. The resulting growth curves for each dilution series were
used to determine MIC values for all test compounds and extracts. Normaliza-
tion of data and creation of BioMAP profiles were accomplished as follows:
(1) Bacterial strains, for which test compounds were inactive, are tempo-
rarily removed from calculation
(2) The remaining MIC values are divided by the largest value in the series
to create a concentration-independent ratio of activities
(3) The reciprocal of each value ismultiplied by 10 and converted to a log10
value
(4) The resulting values are again divided by the largest value in the series
to normalize the highest value to 1, and 0 is introduced as the value for
all bacteria for which the test compound was inactive
(5) Histograms are plotted of bacterium versus BioMAP value.
Hierarchical clustering was performed with Cluster 3.0 (de Hoon et al., 2004)
using Pearson correlation similarity metrics and average linkage clustering
method. To compare the activity profiles of the whole data set of our marine
natural product extracts with the pure antibiotics training set, hierarchical5, November 21, 2012 ª2012 Elsevier Ltd All rights reserved 1493
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iment Viewer (MeV) version 4.8.1 (Saeed et al., 2003). Visualization of the re-
sulting hierarchical cluster was performed with Cytoscape version 2.8.2
(Smoot et al., 2011) as a circular cladogram layout using the phylogenetic
tree plugin.
Isolation, Purification, and Structure Elucidation of Arromycin
The organism that produces arromycin (prefraction 1431E) was originally
isolated from an unidentified sponge sample (brown cylindrical with soft white
projections) collected by self-contained underwater breathing apparatus at
Pinnacles, Monterey Bay, California (36333.5340N, 12157.9640W) West of
Arrow Point, from a depth of 45 ft. The sponge sample was collected into
a sterile 15ml Falcon tube and groundwith a sterile glass rod. The supernatant
was diluted 100-fold with sterile sea water before plating on IM3 agar
(Hong et al., 2009). The isolate was repeatedly subcultured on Difco Marine
Broth plates until pure. The strain was identified as Streptomyces sp. using
16S ribosomal DNA sequence analysis of 1,412 bp (GenBank accession
number JQ964243), with 99% similarity to the closest homolog (seven
mismatched nucleotides). Purification of arromycin was performed using
standard methods (Supplemental Experimental Procedures) to give 73 mg
of a dark orange crystalline solid. A high resolution mass spectrum was
acquired by electrospray ionization Fourier transfer mass spectrometer at
the University of California, Berkeley QB3/Chemistry Mass Spectrometry
Facility. One- and two-dimensional NMR spectra were obtained using a Varian
Unity Inova spectrometer at 600 MHz equipped with a 5 mm HCN triple reso-
nance cryoprobe. Spectra were referenced to residual solvent signals (dH 2.50
and dC 39.5 for d6-DMSO). X-ray crystallography experimental details are
provided in Supplemental Experimental Procedures. Cambridge Crystallo-
graphic Data Centre (CCDC) 902231 contains the supplementary crystallo-
graphic data for this paper. These data can be obtained free of charge from
The Cambridge Crystallographic Data Centre via http://www.ccdc.cam.ac.
uk/data_request/cif.
Minimum Inhibitory Concentration and Cytotoxicity Screening
for Arromycin
Antibacterial activity of arromycin was determined for all strains, against
which the original extract showed activity in the BioMAP profile (B. subtilis,
E. faecium, L. ivanovii, S. epidermis, S. aureus, and MRSA). Arromycin was
serially diluted (final concentration of 100 mM to 12.5 nM, 2-fold dilutions),
and these dilutions were screened using the procedure previously described
above.
For cytotoxicity screening, HeLa cells were plated at a density of 2,000 cells
per well (25 ml) into two 384 well clear bottom plates (Costar 3712) in Dulbec-
co’s modified Eagle’s medium with 10% fetal bovine serum. After 24 hr
incubation at 37C with 5% CO2, test compounds were added (150 nl). After
further incubation for 17 hr at 37C in 5% CO2, the cells were fixed with 4%
formaldehyde and washed with PBS (BioTek ELx405). After standing for
10 min in PBS with 0.5% Triton X-100, the plates were washed and blocked
with 2% BSA in PBS. Nuclei were stained with Hoechst 33342 then washed
with 40 ml of PBS. Plates were imaged using the ImageXpress Micro epifluor-
escent scope (Molecular Devices). MetaXpress software was used to quantify
the total number of cells (nuclear count) for each well, and nuclear counts for
compound treated and control wells were used to calculate LD50 values using
Prism (GraphPad).
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